British researchers have confirmed that there is a drug that is usually prescribed To treat multiple sclerosis Help reduce the risk of serious illness from the Coronavirus, but more research is needed to show whether the drug, which calms the immune system, can really help people with severe coronavirus infection.
Wofka Lashbk ” CNN“The American researchers found that the new beta version of the British biotechnology company Synairgen From interferon beta-1a , Which was reused to treat Covid-19 Increased the potential for improvement and recovery among patients Covid-19 In the hospital in a phase two experiment.
The researchers wrote in a journal The Lancet Respiratory Medicine “The drug reduced the risk of serious illness or death from the Coronavirus by 79%.”
Multiple sclerosis and Corona patients–
The drug is an inhaled combination of an interferon beta-1a, usually used to reduce inflammation and reduce nerve damage caused by multiple sclerosis. In the trial, 48 patients were given a nebulizer while 50 patients received a placebo.
The researchers found that after two weeks, patients who received the daily treatment were twice as likely to improve by day 15 or 16, and three times more than those who received the placebo. However, the researchers write that “there was no significant difference between the treatment groups in Possibilities of discharge from hospital or time of discharge. “
Within two weeks of treatment, the researchers found, 21 patients had recovered 44% – in the group of disease compared to 11 patients – or 22% – in the placebo group. Then by day 28, 58% had recovered in a group SNG001 Compared to 35% in the placebo group, and overall, 3 patients died during the study and were all in the placebo group.
The researchers also found that 11 patients – or 22% – in the placebo group developed severe disease by Day 16 compared to six patients – or 13%, and the most common adverse event in the treatment group was headache.
The researchers wrote in the study: “The drug is a treatment that has already been studied and has been shown to be well tolerated in patients with asthma and COPD. It appears to be well tolerated also in hospitalized patients with disease. COVID-19These encouraging data provide a strong rationale for larger international studies in the context of the ongoing clinical burden of COVID-19.”
According to international experts in lung diseases, they speculated that a phase III trial would likely be needed.
– .
